News
Video
Future Perspectives in ADCs for Treating Advanced NSCLC
Author(s):
Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.
Video Player is loading.
Related Videos
Key Updates in the Treatment of ES-SCLC
Expert Insights on Recent Advancements in LS-SCLC
Logistical Considerations for Delivering TCR Therapy to Patients
Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens
SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC
Key Takeaways and Future Perspectives for In-House Biomarker Testing
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases
Approaches to First-Line Treatment for Synovial Sarcoma
Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity
Related Content
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
